Department of Defense PTSD Adaptive Platform Trial - Master Protocol

Paused · Phase 2 · Has a placebo group

Conditions studied: Post Traumatic Stress Disorder

In brief

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Participants are randomized among the available cohorts in the study and the resulting randomization enables sharing/pooling of control participants, where all interventions may be compared to a common control (placebo). The master protocol describes the default procedures and analyses for all cohorts; treatment-specific eligibility requirements, safety and efficacy procedures, or endpoints are described in the cohort-specific appendices and reflected in the intervention-specific clinicaltrials.gov records.

Key facts

Study ID
NCT05422612
Run by
Global Coalition for Adaptive Research
People needed
800
Starts
2023-11-02
Expected to finish
2029-07-01
Last updated by the study team
2026-06-30

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.